A5013667822- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Immune cells in cancer
- Prostate Cancer Treatment and Research
- Biosimilars and Bioanalytical Methods
- Immunotherapy and Immune Responses
- Immunodeficiency and Autoimmune Disorders
- Phagocytosis and Immune Regulation
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Epigenetics and DNA Methylation
- Peptidase Inhibition and Analysis
- Cancer, Stress, Anesthesia, and Immune Response
- Glycosylation and Glycoproteins Research
- Histone Deacetylase Inhibitors Research
- T-cell and B-cell Immunology
- Click Chemistry and Applications
- Cancer Research and Treatments
- Cancer, Lipids, and Metabolism
- Pancreatitis Pathology and Treatment
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
- Nanoplatforms for cancer theranostics
- Ubiquitin and proteasome pathways
Johns Hopkins University
2017-2023
University of Baltimore
2022
Johns Hopkins Medicine
2017-2021
Howard Hughes Medical Institute
2015-2016
University of California, Berkeley
2015-2016
Stanford University
2016
Solid tumors elicit a detectable immune response including the infiltration of tumor-associated macrophages (TAMs). Unfortunately, this is co-opted into contributing toward tumor growth instead preventing its progression. We seek to reestablish an antitumor by selectively targeting surface receptors and endogenous signaling processes macrophage subtypes driving cancer RP-182 synthetic 10-mer amphipathic analog host defense peptides that induces conformational switch mannose receptor CD206...
Reagents for detecting post-translational modifications in the context of their protein scaffold are powerful tools, but challenging to develop glycosylated epitopes. We describe a strategy protein-specific glycosylation through use cyclooctyne-aptamer conjugates. These molecules selectively ligate azidosugar-labeled glycans exclusively on target live cells. characterized aptamer conjugates against two different cell surface glycoproteins and show that these reagents amenable sialoforms by...
We report a non-destructive biochemical technique, termed "Glyco-seek", for analysis of O-GlcNAcylated proteins. Glyco-seek combines chemoenzymatic labeling, proximity ligation, and quantitative polymerase chain reaction to detect proteins with ultrahigh sensitivity. Our glycan-specific assay can be paired traditional ligation assays simultaneously determine the change in total protein levels. show that detects attomoles glycoproteins interest from cell lysates, sensitivity several orders...
Tumor-associated macrophages (TAMs) are an abundant tumor-promoting cell type in the tumor microenvironment (TME). Most TAMs exhibit a pro-tumor M2-like phenotype supportive of growth, immune evasion, and metastasis. IL-4 IL-13 major cytokines that polarize to M2 subset share common receptor, receptor alpha (IL-4R alpha). Treatment human ex vivo polarized macrophage precursors with IL-4R antagonist antibody Dupilumab (DupixentⓇ) reduces features, including shift surface marker protein...
T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) is an receptor on immune cells that outcompetes activating receptor, CD226, for shared ligands. Tumor-infiltrating lymphocytes express TIGIT CD226 regulatory T (Treg) CD8+ tumor-reactive or exhausted phenotypes, supporting the potential of therapeutically targeting to enhance antitumor immunity. To optimize efficacy therapeutic antibodies against TIGIT, it necessary understand IgG Fc (Fcγ) binding...
Abstract Background Tumor‐associated macrophages (TAMs) are critical components of the tumor microenvironment (TME) in prostate cancer. Commonly used orthotopic models do not accurately reflect complete TME a human patient or natural initiation and progression tumor. Therefore, genetically engineered mouse essential for studying as well advancing TAM‐targeted therapies. Two common transgenic (TG) cancer Hi‐Myc adenocarcinoma (TRAMP), but TAM characteristics these have been characterized....
The prostate cancer tumor microenvironment (TME) is comprised of many cell types that can contribute to and influence progression. Some the most abundant TME cells are macrophages, which be modeled on a continuous spectrum M1-like (anti-tumor macrophages) M2-like (pro-tumor macrophages). A function macrophages efferocytosis, phagocytosis apoptotic cells. Based literature from other models contexts, efferocytosis further supports macrophage phenotype. MerTK receptor tyrosine kinase mediates...
Abstract Macrophage tumor infiltration in metastatic prostate cancer is a predictor of patient prognosis. Macrophages influence tumors contrasting ways depending on their polarization: M1 macrophages have anti-tumor functions while M2 are pro-tumor. The external stimuli influencing macrophage differentiation and polarization been largely elucidated but the resulting downstream changes remain unknown. There number epigenetic differences between that act as important functional determinants....
<p>Figure S1</p>
<div>Abstract<p>T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) is an receptor on immune cells that outcompetes activating receptor, CD226, for shared ligands. Tumor-infiltrating lymphocytes express TIGIT CD226 regulatory T (Treg) CD8<sup>+</sup> tumor-reactive or exhausted phenotypes, supporting the potential of therapeutically targeting to enhance antitumor immunity. To optimize efficacy therapeutic antibodies against...
<p>Figure S9</p>
<p>Supplemental Tables 1–3</p>
<p>Figure S10</p>
<p>Figure S9</p>
<p>Figure S8</p>
<p>Figure S10</p>
<p>Figure S1</p>
<p>Supplemental Tables 1–3</p>
<div>Abstract<p>T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) is an receptor on immune cells that outcompetes activating receptor, CD226, for shared ligands. Tumor-infiltrating lymphocytes express TIGIT CD226 regulatory T (Treg) CD8<sup>+</sup> tumor-reactive or exhausted phenotypes, supporting the potential of therapeutically targeting to enhance antitumor immunity. To optimize efficacy therapeutic antibodies against...
<p>Figure S8</p>
<p>Figure S5</p>
<p>Figure S7</p>